Holen Sie sich die Stockscreener-App
6.53
3.82%
0.24
Vorhandelsmarkt:
6.53
Schlusskurs vom Vortag:
$6.29
Offen:
$6.31
24-Stunden-Volumen:
719.28K
Relative Volume:
0.42
Marktkapitalisierung:
$351.49M
Einnahmen:
$217.25M
Nettoeinkommen (Verlust:
$-50.92M
KGV:
-6.53
EPS:
-1
Netto-Cashflow:
$-100.85M
1W Leistung:
+4.98%
1M Leistung:
+14.16%
6M Leistung:
-54.75%
1J Leistung:
-73.22%
1-Tages-Spanne:
$6.29
$6.59
1-Wochen-Bereich:
$6.185
$6.621
52-Wochen-Spanne:
$4.32
$25.42
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Vergleichen Sie PRTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
6.53 | 334.80M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Prothena Corporation plc (NASDAQ:PRTA) Receives $31.50 Average Price Target from Analysts - Defense World
Prothena Corporation plc Stock Analysis and ForecastFree Stock Market Forecast Reports - jammulinksnews.com
Is Prothena Corporation plc a good long term investmentExceptional gains - jammulinksnews.com
What drives Prothena Corporation plc stock priceRecord-breaking gains - jammulinksnews.com
What analysts say about Prothena Corporation plc stockRapid portfolio appreciation - jammulinksnews.com
How to Take Advantage of moves in (PRTA) - news.stocktradersdaily.com
Why Prothena Corporation plc stock attracts strong analyst attentionFree Smart Investment Opportunities - Newser
What makes Prothena Corporation plc stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
How Prothena Corporation plc stock performs during market volatilityFree Capital Allocation Plans - Newser
Cambridge Investment Research Advisors Inc. Acquires Shares of 10,164 Prothena Corporation plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? - sharewise.com
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - MSN
Prothena to lay off majority of staff; Zealand shares obesity drug data - BioPharma Dive
Peninsula biotech will cut half its workforce, but partner takes Parkinson's drug into late-stage trial - The Business Journals
Prothena announces 63% workforce reduction following birtamimab halt - Investing.com
Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus
Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus
Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks
Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus
Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus
Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus
Prothena to cut workforce by 63% amid strategic review - Investing.com
Prothena announces corporate restructuring - MarketScreener
Prothena Announces Corporate Restructuring - Business Wire
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World
Roche And Prothena: Why Moving On Makes Sense (OTCMKTS:RHHBY) - Seeking Alpha
(PRTA) Trading Signals - news.stocktradersdaily.com
Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX
Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha
Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks
Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com
Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus
Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com
Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa
Cantor Fitzgerald Forecasts Prothena FY2026 Earnings - Defense World
Two Sigma Investments LP Buys 27,887 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):